You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(603259.SH)前三季度扣非淨利潤升36.88%至17.14億元
格隆匯 10-30 20:09

格隆匯10月30日丨藥明康德(603259.SH)發佈2019年前三季度報告,實現營業收入92.79億元,同比增長34.06%;歸屬於上市公司股東的淨利潤17.65億元,同比下降8.46%;歸屬於上市公司股東的扣除非經常性損益的淨利潤17.14億元,同比增長36.88%;基本每股收益1.08元。

公司是全球領先的藥物研發服務平台,總部設於中國上海,通過中國、美國及歐洲等全球各地設有29個運營基地和分支機構為超過3700家客户提供小分子化學藥的發現、研發及生產的全方位、一體化平台服務,以全產業鏈平台的形式面向全球製藥企業提供各類新藥的研發、生產及配套服務,並開展部分醫療器械檢測及精準醫療研發生產服務。截至本報告期末,公司共擁有21463名員工,其中7395名獲得碩士或以上學位,1002名獲得博士或同等學位。

報告期,歸屬於上市公司股東的淨利潤下降8.46%,主要系公司所投資標的公允價值變動損失4539.67萬元,較上年同期公允價值變動收益6.69億元大幅減少7.14億元所致。扣除所投資標的公允價值變動影響後,公司報告期歸屬於上市公司股東的淨利潤較上年同期增長43.74%。

報告期加權平均淨資產收益率下降12.73個百分點,主要系公司2018年12月於香港聯交所上市發行H股,導致淨資產餘額增長使得加權平均淨資產收益率下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account